4D Molecular Therapeutics (FDMT) Cash from Investing Activities Growth (1y) (2021 - 2026)
4D Molecular Therapeutics (FDMT) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7,936.68% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 26.37% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -157.08% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -89.24% |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 284.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 284.41% |
| Mar 31, 2026 | 115.63% |
| Dec 31, 2025 | -1,925.29% |
| Sep 30, 2025 | -34.88% |
| Jun 30, 2025 | 81.16% |
| Mar 31, 2025 | 112.14% |
| Dec 31, 2024 | 205.64% |
| Sep 30, 2024 | -8.94% |
| Jun 30, 2024 | -249.20% |
| Mar 31, 2024 | -710.38% |
| Dec 31, 2023 | 81.32% |
| Sep 30, 2023 | 95.05% |
| Jun 30, 2023 | -14.23% |
| Mar 31, 2023 | 179.71% |
| Dec 31, 2022 | -10.80% |
| Sep 30, 2022 | 111.06% |
| Jun 30, 2022 | 7,897.56% |
| Mar 31, 2022 | -8,328.35% |
| Dec 31, 2021 | -6,256.50% |
| Sep 30, 2021 | -39,930.95% |